Ariel Precision Medicine utilizes the ADVANCE® platform to analyze genetic, environmental, and patient-specific data, providing personalized risk assessments for complex diseases like pancreatitis and pancreatic cancer. This approach enables early detection and tailored treatment strategies, enhancing patient outcomes and quality of life.
Funding
Funding not disclosed
Founders
Product
Problem
Complex diseases like pancreatitis and pancreatic cancer often stem from a combination of genetic, environmental, and patient-specific risk factors, making it difficult to provide targeted and effective care. Traditional diagnostic approaches may not fully account for this individual variability, potentially leading to delayed or inaccurate diagnoses. This can result in suboptimal treatment strategies and reduced quality of life for patients.
Solution
Ariel Precision Medicine offers the ADVANCE® platform, a precision medicine solution that analyzes a patient's unique combination of genetic predispositions, environmental exposures, and health history to provide personalized risk assessments for complex diseases. By integrating these data points with clinical guidance and current scientific evidence, the platform delivers actionable insights that inform early detection, risk-reducing strategies, and tailored treatment plans. This comprehensive approach enables healthcare providers to move beyond generalized treatments and deliver personalized care that addresses the specific needs of each patient, ultimately improving outcomes and quality of life. The platform supports proactive screening and monitoring, allowing for earlier intervention and potentially preventing disease progression.
Target Audience
The primary target audience includes healthcare providers, such as gastroenterologists and oncologists, seeking to improve the diagnosis and treatment of complex diseases like pancreatitis and pancreatic cancer, as well as clinical researchers.
Features
- Combines genetic testing results with medical history, patient health profile, and lifestyle factors for a comprehensive risk assessment.
- Employs the ADVANCE® platform to analyze complex data sets and identify individual risk factors.
- Delivers personalized reports with actionable insights to guide screening, risk reduction, and treatment decisions.
- Provides clinical guidance supported by current scientific evidence.
- Offers array genotyping and bioinformatics & NGS services for researchers.